Analysts Issue Forecasts for PRQR FY2025 Earnings

ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for ProQR Therapeutics in a research report issued on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the biopharmaceutical company will post earnings per share of ($0.39) for the year. Cantor Fitzgerald has a "Overweight" rating and a $8.00 price target on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.31) per share.

Other equities research analysts have also recently issued research reports about the company. Citigroup raised ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price for the company in a research note on Monday, March 10th. Oppenheimer initiated coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They issued an "outperform" rating and a $15.00 price objective on the stock. HC Wainwright increased their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Friday, March 14th. Chardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, March 14th. Finally, Evercore ISI assumed coverage on shares of ProQR Therapeutics in a research report on Tuesday, April 29th. They set an "outperform" rating and a $5.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $8.75.

ProQR Therapeutics Stock Performance

Shares of NASDAQ PRQR traded down $0.27 during midday trading on Thursday, reaching $1.54. 602,037 shares of the stock were exchanged, compared to its average volume of 612,253. The stock has a market capitalization of $161.50 million, a P/E ratio of -4.80 and a beta of 0.35. The company has a 50 day simple moving average of $1.55 and a 200 day simple moving average of $2.45. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.62.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in ProQR Therapeutics in the 4th quarter valued at about $30,000. Invesco Ltd. purchased a new position in shares of ProQR Therapeutics in the 4th quarter valued at about $32,000. Alpine Global Management LLC acquired a new stake in shares of ProQR Therapeutics during the 4th quarter worth about $39,000. Two Sigma Securities LLC purchased a new stake in ProQR Therapeutics during the fourth quarter worth approximately $40,000. Finally, Vontobel Holding Ltd. purchased a new position in ProQR Therapeutics in the first quarter valued at approximately $48,000. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).